NIH R01 · 2024
Assessing Optimal XR-Buprenorphine Initiation Points in Jail
The prevalence of opioid use disorder (OUD) is especially high among individuals supervised by the criminal justice system (CJS), and a preponderance of opioid overdose deaths occur among individuals who have a history of CJS involvement (Binswanger et al., 2007; Bird et al., 2016). Because of the high prevalence of opioid use among CJS populations, jails offer a unique opportunity to identify and treat persons with OUD. In 2017, the FDA approved an extended-release formulation of buprenorphine (XR-B, Sublocade®; Indivior, Inc.) with subcutaneous injections of 100mg or 300mg buprenorphine delivered every four weeks. Early evaluations of XR-B in community setting show relatively high…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.